Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex

被引:1076
|
作者
Brugarolas, J
Lei, K
Hurley, RL
Manning, BD
Reiling, JH
Hafen, E
Witter, LA
Ellisen, LW
Kaelin, WG [1 ]
机构
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Brigham & Womens Hosp, Boston, MA 02115 USA
[3] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02116 USA
[4] Dartmouth Coll, Dept Med & Biochem, Dartmouth Med Sch, Hanover, NH 03755 USA
[5] Dartmouth Coll, Dept Sci Biol, Hanover, NH 03755 USA
[6] Harvard Univ, Sch Publ Hlth, Dept Genet & Complex Dis, Boston, MA 02115 USA
[7] Univ Zurich, Inst Zool, CH-8057 Zurich, Switzerland
[8] Howard Hughes Med Inst, Chevy Chase, MD 20815 USA
关键词
tuberous sclerosis complex; TSC1; TSC2; REDD1/RTP801; mTOR; hypoxia;
D O I
10.1101/gad.1256804
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Mammalian target of rapamycin (mTOR) is a central regulator of protein synthesis whose activity is modulated by a variety of signals. Energy depletion and hypoxia result in mTOR inhibition. While energy depletion inhibits mTOR through a process involving the activation of AMP-activated protein kinase (AMPK) by LKB1 and subsequent phosphorylation of TSC2, the mechanism of mTOR inhibition by hypoxia is not known. Here we show that mTOR inhibition by hypoxia requires the TSC1/TSC2 tumor suppressor complex and the hypoxia-inducible gene REDD1/RTP801. Disruption of the TSC1/TSC2 complex through loss of TSC1 or TSC2 blocks the effects of hypoxia on mTOR, as measured by changes in the mTOR targets S6K and 4E-BP1, and results in abnormal accumulation of Hypoxia-inducible factor (HIF). In contrast to energy depletion, mTOR inhibition by hypoxia does not require AMPK or LKB1. Down-regulation of mTOR activity by hypoxia requires de novo mRNA synthesis and correlates with increased expression of the hypoxia-inducible REDD1 gene. Disruption of REDD1 abrogates the hypoxia-induced inhibition of mTOR, and REDD1 overexpression is sufficient to down-regulate S6K phosphorylation in a TSC1/TSC2-dependent manner. Inhibition of mTOR function by hypoxia is likely to be important for tumor suppression as TSC2-deficient cells maintain abnormally high levels of cell proliferation under hypoxia.
引用
收藏
页码:2893 / 2904
页数:12
相关论文
共 50 条
  • [31] Regionally specific TSC1 and TSC2 gene expression in tuberous sclerosis complex
    Yi Li
    Matthew J. Barkovich
    Celeste M. Karch
    Ryan M. Nillo
    Chun-Chieh Fan
    Iris J. Broce
    Chin Hong Tan
    Daniel Cuneo
    Christopher P. Hess
    William P. Dillon
    Orit A. Glenn
    Christine M. Glastonbury
    Nicholas Olney
    Jennifer S. Yokoyama
    Luke W. Bonham
    Bruce Miller
    Aimee Kao
    Nicholas Schmansky
    Bruce Fischl
    Ole A. Andreassen
    Terry Jernigan
    Anders Dale
    A. James Barkovich
    Rahul S. Desikan
    Leo P. Sugrue
    Scientific Reports, 8
  • [32] Mutation landscape of TSC1/TSC2 in Chinese patients with tuberous sclerosis complex
    Yuhuan Meng
    Changshun Yu
    Meijun Chen
    Xiaokang Yu
    Mingming Sun
    Hui Yan
    Weiwei Zhao
    Shihui Yu
    Journal of Human Genetics, 2021, 66 : 227 - 236
  • [33] Clinical utility gene card for: Tuberous sclerosis complex (TSC1, TSC2)
    Mayer, Karin
    Fonatsch, Christa
    Wimmer, Katharina
    van den Ouweland, Ans M. W.
    Maat-Kievit, Anneke J. A.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2014, 22 (02) : 293 - 293
  • [34] TSC1 stabilizes TSC2 by inhibiting the interaction between TSC2 and the HERC1 ubiquitin ligase
    Chong-Kopera, H
    Inoki, K
    Li, Y
    Zhu, TQ
    Garcia-Gonzalo, FR
    Rosa, JL
    Guan, KL
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (13) : 8313 - 8316
  • [35] Clinical utility gene card for: Tuberous sclerosis complex (TSC1, TSC2)
    Karin Mayer
    Christa Fonatsch
    Katharina Wimmer
    Ans MW van den Ouweland
    Anneke JA Maat-Kievit
    European Journal of Human Genetics, 2014, 22 : 293 - 293
  • [36] TSC1 and TSC2: Tuberous Sclerosis Complex and Its Related Epilepsy Phenotype
    Di Napoli, Claudia
    Gennaro, Alessia
    Lupica, Carmelania
    Falsaperla, Raffaele
    Leonardi, Roberta
    Garozzo, Maria Teresa
    Polizzi, Agata
    Pratico, Andrea D.
    Zanghi, Antonio
    Ruggieri, Martino
    JOURNAL OF PEDIATRIC NEUROLOGY, 2023, 21 (04) : 235 - 247
  • [37] PTEN expression and mutations in TSC1, TSC2 and MTOR are associated with response to rapalogs in patients with renal cell carcinoma
    Roldan-Romero, Juan M.
    Beuselinck, Benoit
    Santos, Maria
    Rodriguez-Moreno, Juan F.
    Lanillos, Javier
    Calsina, Bruna
    Gutierrez, Ana
    Tang, Karin
    Lainez, Nuria
    Puente, Javier
    Castellano, Daniel
    Esteban, Emilio
    Climent, Miguel A.
    Arranz, Jose A.
    Albersen, Maarten
    Oudard, Stephane
    Couchy, Gabrielle
    Caleiras, Eduardo
    Montero-Conde, Cristina
    Cascon, Alberto
    Robledo, Mercedes
    Rodriguez-Antona, Cristina
    Garcia-Donas, Jesus
    Pinto, Alvaro
    Hernando-Polo, Susana
    Grande, Enrique
    Domenech, Montserrat
    Antonio Virizuela, Juan
    Saez, Maria Isabel
    Rodriguez-Lajusticia, Laura
    Duran, Ignacio
    Gonzalez-Billalabeitia, Enrique
    Gallardo, Enrique
    Gonzalez del Alba, Aranzazu
    Bellmunt, Joaquim
    Mellado, Begona
    Font, Albert
    Alonso-Gordoa, Teresa
    INTERNATIONAL JOURNAL OF CANCER, 2020, 146 (05) : 1435 - 1444
  • [38] TSC1–TSC2: a complex tale of PKB-mediated S6K regulation
    Edward J. McManus
    Dario R. Alessi
    Nature Cell Biology, 2002, 4 : E214 - E216
  • [39] Mutational analysis of TSC1 and TSC2 in Korean patients with tuberous sclerosis complex
    Choi, Ji-Eun
    Chae, Jong-Hee
    Hwang, Yong-Seung
    Kim, Ki-Joong
    BRAIN & DEVELOPMENT, 2006, 28 (07): : 440 - 446
  • [40] Mutational and expression analysis of the TSC1 and TSC2 genes in gangliogliomas
    Becker, A
    Loebach, M
    Normann, S
    Klein, H
    Noethen, M
    von Deimling, A
    Mizuguchi, M
    Elger, CE
    Schramm, J
    Wiestler, OD
    Blumcke, I
    BRAIN PATHOLOGY, 2000, 10 (04) : 600 - 601